BR112013001429A2 - método de identificação de pacientes com maior probabilidade de responder a terapia anticâncer - Google Patents
método de identificação de pacientes com maior probabilidade de responder a terapia anticâncerInfo
- Publication number
- BR112013001429A2 BR112013001429A2 BR112013001429A BR112013001429A BR112013001429A2 BR 112013001429 A2 BR112013001429 A2 BR 112013001429A2 BR 112013001429 A BR112013001429 A BR 112013001429A BR 112013001429 A BR112013001429 A BR 112013001429A BR 112013001429 A2 BR112013001429 A2 BR 112013001429A2
- Authority
- BR
- Brazil
- Prior art keywords
- respond
- anticancer therapy
- identifying patients
- patients
- identifying
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10170004 | 2010-07-19 | ||
EP10170008 | 2010-07-19 | ||
US41485910P | 2010-11-17 | 2010-11-17 | |
US201161497757P | 2011-06-16 | 2011-06-16 | |
PCT/EP2011/062227 WO2012010547A1 (en) | 2010-07-19 | 2011-07-18 | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013001429A2 true BR112013001429A2 (pt) | 2016-05-31 |
Family
ID=45496541
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013001433A BR112013001433A2 (pt) | 2010-07-19 | 2011-07-18 | método de identificação de pacientes com maior probabilidade de responder a terapia anticâncer |
BR112013001429A BR112013001429A2 (pt) | 2010-07-19 | 2011-07-18 | método de identificação de pacientes com maior probabilidade de responder a terapia anticâncer |
BR112013001431A BR112013001431A2 (pt) | 2010-07-19 | 2011-07-18 | método de identificação de pacientes com maior probabilidade de reação a terapia anticâncer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013001433A BR112013001433A2 (pt) | 2010-07-19 | 2011-07-18 | método de identificação de pacientes com maior probabilidade de responder a terapia anticâncer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013001431A BR112013001431A2 (pt) | 2010-07-19 | 2011-07-18 | método de identificação de pacientes com maior probabilidade de reação a terapia anticâncer |
Country Status (14)
Country | Link |
---|---|
US (12) | US20130344059A1 (pt) |
EP (8) | EP2596361A1 (pt) |
JP (8) | JP2013534305A (pt) |
KR (5) | KR20130126588A (pt) |
CN (8) | CN103180738A (pt) |
AU (4) | AU2011281701A1 (pt) |
BR (3) | BR112013001433A2 (pt) |
CA (4) | CA2805709A1 (pt) |
HK (1) | HK1216039A1 (pt) |
MX (4) | MX2013000674A (pt) |
RU (4) | RU2013104302A (pt) |
SG (8) | SG10201505601RA (pt) |
WO (4) | WO2012010547A1 (pt) |
ZA (3) | ZA201300305B (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
AU2012348600A1 (en) * | 2011-12-05 | 2014-05-22 | F. Hoffmann-La Roche Ag | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
US9116159B2 (en) | 2012-05-22 | 2015-08-25 | Regeneron Pharmaceuticals, Inc. | VEGF-A121 assay |
KR20150024342A (ko) * | 2012-06-26 | 2015-03-06 | 에프. 호프만-라 로슈 아게 | 유방암을 치료하기 위한 베바시주맙 조합 요법에 대한 혈장 바이오마커 |
US9953417B2 (en) * | 2013-10-04 | 2018-04-24 | The University Of Manchester | Biomarker method |
LT3524595T (lt) | 2014-08-28 | 2022-09-26 | Eisai R&D Management Co., Ltd. | Aukšto grynumo chinolino darinys ir jo gamybos būdas |
MX2017003387A (es) * | 2014-09-16 | 2018-01-30 | Regeneron Pharma | Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogenetica de cancer colorrectal metastasico. |
WO2016065626A1 (zh) * | 2014-10-31 | 2016-05-06 | 深圳市大疆创新科技有限公司 | 一种气体泄漏的处理方法、装置及飞行器 |
EP3218401B1 (en) * | 2014-11-14 | 2020-03-04 | F. Hoffmann-La Roche AG | Predicting response to a vegf antagonist |
RS65049B1 (sr) | 2015-02-25 | 2024-02-29 | Eisai R&D Man Co Ltd | Metoda za suzbijanje gorčine derivata kinolina |
WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
NZ735803A (en) * | 2015-04-02 | 2021-12-24 | Molecular Partners Ag | Designed ankyrin repeat domains with binding specificity for serum albumin |
WO2016204193A1 (ja) | 2015-06-16 | 2016-12-22 | 株式会社PRISM Pharma | 抗がん剤 |
AU2017211247B2 (en) * | 2016-01-25 | 2023-03-09 | Sanofi | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker |
CN109477843A (zh) * | 2016-07-15 | 2019-03-15 | 豪夫迈·罗氏有限公司 | 用于检测总vegf-a的水平的方法和手段 |
RU2639253C1 (ru) * | 2016-12-30 | 2017-12-20 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ прогнозирования эффективности пролонгированной лучевой терапии при раке прямой кишки |
CN108753984B (zh) * | 2018-08-28 | 2021-07-13 | 北京市神经外科研究所 | 预测或诊断脑恶性胶质瘤术后复发的生物标志物组合及其应用和试剂盒 |
WO2020159203A1 (ko) * | 2019-01-29 | 2020-08-06 | (주)엠디바이오랩 | 스트렙토니그린 및 항암제를 포함하는 뇌종양 예방 또는 치료용 조성물 |
JP7485273B2 (ja) | 2020-06-25 | 2024-05-16 | 国立大学法人 鹿児島大学 | 抗vegf-a抗体による癌に対する治療応答性を予測又は決定するための方法 |
KR102261368B1 (ko) | 2020-09-16 | 2021-06-08 | 주식회사 라이브러리엔 | 자유로운 조합 구성이 가능한 조립식 소파 |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
CA2134773A1 (en) | 1992-06-04 | 1993-12-09 | Robert J. Debs | Methods and compositions for in vivo gene therapy |
EP0666868B2 (en) | 1992-10-28 | 2006-06-14 | Genentech, Inc. | Use of anti-VEGF antibodies for the treatment of cancer |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
EP1709970A1 (en) | 1995-04-27 | 2006-10-11 | Abgenix, Inc. | Human antibodies against EGFR, derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
ATE211134T1 (de) | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
PL331154A1 (en) | 1996-07-13 | 1999-06-21 | Glaxo Group Ltd | Bicyclic heteroaromatic compounds as inhibitors of proteinous tyrosine kinase |
EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
SI0971959T1 (sl) | 1997-04-07 | 2006-06-30 | Genentech Inc | Humanizirana protitelesa in postopki za tvorbo humaniziranih protiteles |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
DE69829891T2 (de) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
WO1998050356A1 (en) | 1997-05-07 | 1998-11-12 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
WO1998054093A1 (en) | 1997-05-30 | 1998-12-03 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
ES2289791T3 (es) | 1997-08-22 | 2008-02-01 | Astrazeneca Ab | Derivados de oxindolilquinazolina como inhibidores de la angiogenesis. |
AU744939B2 (en) | 1997-09-26 | 2002-03-07 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
CA2309690A1 (en) | 1997-11-11 | 1999-05-20 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
CA2312208C (en) | 1997-12-05 | 2011-01-25 | The Scripps Research Institute | Humanization of murine antibody |
JP3591264B2 (ja) * | 1997-12-24 | 2004-11-17 | 富士レビオ株式会社 | Vegf121特異的モノクローナル抗体及び測定方法 |
DE19806989A1 (de) | 1998-02-19 | 1999-08-26 | Roche Diagnostics Gmbh | Erzeugung räumlich scharf begrenzter Festphasen für Bindungsassays |
DK2020408T3 (da) | 1998-05-29 | 2013-09-30 | Sugen Inc | Pyrrol-substitueret 2-indolinon som proteinkinaseinhibitor |
US6387663B1 (en) * | 1998-07-31 | 2002-05-14 | University Of Southern California | Targeting pharmaceutical agents to injured tissues |
CA2359067C (en) | 1999-01-15 | 2017-03-14 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
KR100749982B1 (ko) | 1999-11-16 | 2007-08-16 | 제넨테크, 인크. | 혈관 내피 성장 인자용 elisa |
WO2001077342A1 (en) | 2000-04-11 | 2001-10-18 | Genentech, Inc. | Multivalent antibodies and uses therefor |
US7833525B2 (en) | 2000-12-28 | 2010-11-16 | Bhami Shenoy | Crystals of whole antibodies and fragments thereof and methods for making and using them |
AR042586A1 (es) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
KR20160014775A (ko) | 2003-05-30 | 2016-02-11 | 제넨테크, 인크. | 항-vegf 항체를 사용한 치료 |
US20050009110A1 (en) * | 2003-07-08 | 2005-01-13 | Xiao-Jia Chang | Methods of producing antibodies for diagnostics and therapeutics |
US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
WO2005087812A1 (en) | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for vegf/pdgf family of growth factors |
UA88294C2 (ru) * | 2004-03-24 | 2009-10-12 | Фейсит Биотек Корпорейшен | ПРИМЕНЕНИЕ АНТИ-α5β1 АНТИТЕЛ ДЛЯ УГНЕТЕНИЯ ПРОЛИФЕРАЦИИ РАКОВЫХ КЛЕТОК |
DE102004029909A1 (de) | 2004-06-21 | 2006-01-19 | Roche Diagnostics Gmbh | Verfahren und Vorrichtung zur Herstellung von bindungsfähigen Reagenzträgern |
US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
WO2007145862A2 (en) * | 2006-06-05 | 2007-12-21 | Genentech, Inc. | Extending survival of cancer patients with elevated levels of egf or tgf-alpha |
WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
PL2069798T3 (pl) | 2006-10-04 | 2014-09-30 | Genentech Inc | Test ELISA dla VEGF |
MX2010005057A (es) * | 2007-11-09 | 2010-05-19 | Genentech Inc | Metodos y composiciones para uso de diagnostico en pacientes de cancer. |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
MX350962B (es) | 2008-01-07 | 2017-09-27 | Amgen Inc | Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion. |
SI2274008T1 (sl) * | 2008-03-27 | 2014-08-29 | Zymogenetics, Inc. | Sestavki in metode za zaviranje PDGFRBETA in VEGF-A |
US20100029491A1 (en) * | 2008-07-11 | 2010-02-04 | Maike Schmidt | Methods and compositions for diagnostic use for tumor treatment |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
WO2010075420A1 (en) * | 2008-12-23 | 2010-07-01 | Genentech, Inc. | Methods and compositions for diagnostic use in cancer patients |
PE20120591A1 (es) | 2009-04-02 | 2012-05-23 | Roche Glycart Ag | Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla |
CA2757931C (en) | 2009-04-07 | 2019-03-26 | Roche Glycart Ag | Trivalent, bispecific antibodies |
JP5719354B2 (ja) | 2009-05-27 | 2015-05-20 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 三重又は四重特異性抗体 |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
UY32920A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moleculas de unión biespecíficas para la terapia anti-angiogénesis |
-
2011
- 2011-07-18 CN CN2011800449994A patent/CN103180738A/zh active Pending
- 2011-07-18 EP EP11735862.2A patent/EP2596361A1/en not_active Withdrawn
- 2011-07-18 KR KR1020137004039A patent/KR20130126588A/ko not_active Application Discontinuation
- 2011-07-18 MX MX2013000674A patent/MX2013000674A/es not_active Application Discontinuation
- 2011-07-18 CN CN201410775889.0A patent/CN104634971A/zh active Pending
- 2011-07-18 BR BR112013001433A patent/BR112013001433A2/pt not_active IP Right Cessation
- 2011-07-18 KR KR1020157001119A patent/KR20150013949A/ko not_active Application Discontinuation
- 2011-07-18 AU AU2011281701A patent/AU2011281701A1/en not_active Abandoned
- 2011-07-18 AU AU2011281702A patent/AU2011281702A1/en not_active Abandoned
- 2011-07-18 MX MX2013000675A patent/MX2013000675A/es not_active Application Discontinuation
- 2011-07-18 KR KR1020137004044A patent/KR20130055647A/ko not_active Application Discontinuation
- 2011-07-18 SG SG10201505601RA patent/SG10201505601RA/en unknown
- 2011-07-18 CA CA2805709A patent/CA2805709A1/en not_active Abandoned
- 2011-07-18 JP JP2013520101A patent/JP2013534305A/ja active Pending
- 2011-07-18 EP EP11732485.5A patent/EP2596359A1/en not_active Withdrawn
- 2011-07-18 JP JP2013520102A patent/JP2013537522A/ja not_active Withdrawn
- 2011-07-18 RU RU2013104302/15A patent/RU2013104302A/ru not_active Application Discontinuation
- 2011-07-18 JP JP2013520105A patent/JP2013534307A/ja active Pending
- 2011-07-18 MX MX2013000676A patent/MX2013000676A/es not_active Application Discontinuation
- 2011-07-18 SG SG10201505593VA patent/SG10201505593VA/en unknown
- 2011-07-18 AU AU2011281705A patent/AU2011281705A1/en not_active Abandoned
- 2011-07-18 RU RU2013104301/15A patent/RU2013104301A/ru not_active Application Discontinuation
- 2011-07-18 KR KR1020137004030A patent/KR20130091745A/ko not_active Application Discontinuation
- 2011-07-18 WO PCT/EP2011/062227 patent/WO2012010547A1/en active Application Filing
- 2011-07-18 SG SG10201505595WA patent/SG10201505595WA/en unknown
- 2011-07-18 SG SG2013003868A patent/SG187119A1/en unknown
- 2011-07-18 AU AU2011281704A patent/AU2011281704A1/en not_active Abandoned
- 2011-07-18 EP EP14188054.2A patent/EP2824457A1/en not_active Withdrawn
- 2011-07-18 SG SG2013002035A patent/SG187018A1/en unknown
- 2011-07-18 WO PCT/EP2011/062228 patent/WO2012010548A1/en active Application Filing
- 2011-07-18 CN CN201510296857.7A patent/CN104965084B/zh not_active Expired - Fee Related
- 2011-07-18 EP EP14188048.4A patent/EP2848939A1/en not_active Withdrawn
- 2011-07-18 WO PCT/EP2011/062230 patent/WO2012010550A1/en active Application Filing
- 2011-07-18 SG SG2013003892A patent/SG187121A1/en unknown
- 2011-07-18 EP EP20140188047 patent/EP2866032A1/en not_active Withdrawn
- 2011-07-18 MX MX2013000672A patent/MX2013000672A/es not_active Application Discontinuation
- 2011-07-18 BR BR112013001429A patent/BR112013001429A2/pt not_active IP Right Cessation
- 2011-07-18 CA CA2805618A patent/CA2805618A1/en not_active Abandoned
- 2011-07-18 EP EP11732484.8A patent/EP2596358A1/en not_active Withdrawn
- 2011-07-18 CN CN2011800450690A patent/CN103270418A/zh active Pending
- 2011-07-18 CN CN201510105182.3A patent/CN104730243A/zh active Pending
- 2011-07-18 RU RU2013104300/15A patent/RU2013104300A/ru not_active Application Discontinuation
- 2011-07-18 SG SG2013003884A patent/SG187120A1/en unknown
- 2011-07-18 CN CN201410791040.2A patent/CN104614525A/zh active Pending
- 2011-07-18 EP EP14170386.8A patent/EP2801826A1/en not_active Withdrawn
- 2011-07-18 CA CA2805623A patent/CA2805623A1/en not_active Abandoned
- 2011-07-18 CN CN2011800449797A patent/CN103180736A/zh active Pending
- 2011-07-18 KR KR1020137004034A patent/KR20130126587A/ko not_active Application Discontinuation
- 2011-07-18 RU RU2013104299/15A patent/RU2013104299A/ru not_active Application Discontinuation
- 2011-07-18 JP JP2013520104A patent/JP2013534306A/ja active Pending
- 2011-07-18 CA CA2805708A patent/CA2805708A1/en not_active Abandoned
- 2011-07-18 SG SG10201505414XA patent/SG10201505414XA/en unknown
- 2011-07-18 WO PCT/EP2011/062231 patent/WO2012010551A1/en active Application Filing
- 2011-07-18 EP EP11732486.3A patent/EP2596360A1/en not_active Withdrawn
- 2011-07-18 CN CN201180044980XA patent/CN103180737A/zh active Pending
- 2011-07-18 BR BR112013001431A patent/BR112013001431A2/pt not_active IP Right Cessation
-
2013
- 2013-01-11 ZA ZA2013/00305A patent/ZA201300305B/en unknown
- 2013-01-14 ZA ZA2013/00345A patent/ZA201300345B/en unknown
- 2013-01-16 ZA ZA2013/00440A patent/ZA201300440B/en unknown
- 2013-01-17 US US13/744,140 patent/US20130344059A1/en not_active Abandoned
- 2013-01-17 US US13/744,131 patent/US20130336960A1/en not_active Abandoned
- 2013-01-17 US US13/744,014 patent/US20130336959A1/en not_active Abandoned
- 2013-01-17 US US13/744,135 patent/US20130171135A1/en not_active Abandoned
- 2013-03-13 US US13/802,356 patent/US20140017231A1/en not_active Abandoned
- 2013-03-13 US US13/801,360 patent/US20130243758A1/en not_active Abandoned
- 2013-03-13 US US13/802,379 patent/US20140023639A1/en not_active Abandoned
- 2013-03-13 US US13/802,333 patent/US20140193397A1/en not_active Abandoned
- 2013-03-13 US US13/802,303 patent/US20140056875A1/en not_active Abandoned
- 2013-03-13 US US13/802,394 patent/US20140017232A1/en not_active Abandoned
- 2013-03-13 US US13/801,404 patent/US20130183300A1/en not_active Abandoned
- 2013-03-13 US US13/802,282 patent/US20140056874A1/en not_active Abandoned
- 2013-10-22 HK HK16103925.6A patent/HK1216039A1/zh unknown
-
2015
- 2015-04-24 JP JP2015089690A patent/JP2015206795A/ja active Pending
- 2015-05-01 JP JP2015094412A patent/JP2015180879A/ja active Pending
- 2015-07-22 JP JP2015144659A patent/JP2016014670A/ja active Pending
- 2015-08-21 JP JP2015163347A patent/JP2016026290A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013001429A2 (pt) | método de identificação de pacientes com maior probabilidade de responder a terapia anticâncer | |
IL267547A (en) | Sensing or stimulating tissue activity | |
NL300963I2 (nl) | inotersen of een zout daarvan | |
CY2018029I2 (el) | Αντι-ιικη θεραπεια | |
SMT201500233B (it) | Metodi per rilevare anticorpi anti-farmaco | |
BR112014001854A2 (pt) | sistema implantável de estimulação cardíaca | |
DK2863990T3 (da) | Medicinsk mikroelektrode | |
BR112013012156A2 (pt) | sistema terapêutico transdérmico e método de produção de um sistema terapêutico transdérmico | |
IL230012B (en) | Computer-aided localization of site of origin of cardiac activation | |
BR112013031110A2 (pt) | kit e método de detectar os microrganismos resistentes a um agente terapêutico | |
BR112013033974A2 (pt) | terapia de combinação | |
BR112014007029A2 (pt) | métodos aperfeiçoados de terapia gênica | |
DK2760886T3 (da) | Immunocytokin-kombinationsterapi | |
FI20115876A0 (fi) | Yhdistelmähoito | |
DK2912186T3 (da) | Behandling rettet mod blodplader | |
BR112012028156A2 (pt) | sistema de terapia respiratória e método de fornecimento de terapia respiratória a um paciente | |
SMT201700103B (it) | Bersaglio terapeutico e diagnostico | |
FI20115640A0 (fi) | Yhdistelmähoito | |
BR112014025713A2 (pt) | Ampicilina resistante a texturização das linhagens de bactérias de ácido láctico | |
EP2771864A4 (en) | IDENTIFYING PERSONS WITH PROBABILITY FOR EXACTLY RESPONSIBLE QUESTIONS | |
FR2955473B1 (fr) | Structure de presentoir | |
DK2694056T3 (da) | Terapeutisk behandling | |
BR112013001432A2 (pt) | método para identificar um paciente com uma maior probabilidade de responder e aum terapia anticâncer | |
ES1072514Y (es) | Masajeador corporal | |
ZA201300344B (en) | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |